22 COVID-19 vaccines enter clinical trials in China: health official
Xinhua |
Updated: 2021-07-08 19:36
Share
Share - WeChat
BEIJING - Twenty-two COVID-19 vaccines have been approved to enter clinical trials in China, a health official said Thursday.
To date, four COVID-19 vaccines have been granted conditional marketing approval and three have been authorized for emergency use within the country, said Yuan Lin, an official with the National Medical Products Administration (NMPA), at a press conference in Beijing.
By the end of June, the NMPA had granted emergency approval for clinical trials to 25 drugs intended for the treatment of COVID-19 and its indications, Yuan added.
- China-Vietnam carbon markets explored in new academic work
- UIBE School of International Relations marks 20th anniversary with global governance forum
- San Francisco mayor: so much to see in Shanghai
- Woman gets death sentence with reprieve for abusing boyfriend's 3-year-old son
- China's State Council appoints, removes officials
- Macao university hosts intl conference on regenerative medicine
